The importance of OVA-specific CTLs among tumor infiltrating lymphocytes was suggested by a two-fold increase of OVA-specific CD8 T cells when the OVA/CpG-ODN vaccine was combined with the CD1d-therapy compared to the vaccine alone (Figure 4B). This evidence concerns the gene CD1D and neoplasm.